TRDJ1

Model summary

A soluble human signaling regulator that uses protein–protein interactions to dampen cAMP-driven kinase pathways. By forming inhibitory complexes with cAMP-dependent kinase assemblies and their anchoring scaffolds, it reduces kinase output and reshapes downstream signaling flows. Its activity is centered in the cytosol with regulated access to the nucleus, and it can be packaged into extracellular vesicles, together positioning it to modulate cytoplasmic and nuclear signaling nodes.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The sequence carries a single annotated module: GO:0005515 protein binding. The absence of catalytic InterPro signatures and the presence of a sole binding annotation indicate a non-enzymatic regulator that exerts function through selective protein–protein interactions. A solitary binding-centric architecture typically encodes a scaffold or inhibitor that tunes signaling by docking to target enzymes or adaptors rather than performing chemistry itself.

2. 02

   From this binding-centric core, the most direct molecular function is protein binding (GO:0005515).

   Such binding capacity enables inhibition of cAMP-dependent protein kinase pathways. A binding-driven inhibitory mechanism naturally explains negative regulation of cAMP-dependent protein kinase activity (GO:2000480): by docking to the catalytic or regulatory surfaces of the cAMP-dependent kinase system, the protein dampens kinase output without catalysis. This inhibitory control propagates into broader intracellular signal transduction (GO:0035556), because cAMP–PKA nodes gate diverse pathways; restraining PKA activity rebalances downstream signaling flux.

3. 03

   Cellular localization follows from how such regulators operate.

   The soluble nature of a binding-only polypeptide supports a cytosolic pool, consistent with GO:0005829 cytosol and the experimentally supported cytoplasmic location. Many PKA regulators shuttle to the nucleus to modulate transcriptional programs and nuclear cAMP signaling, aligning with GO:0005634 nucleus. Packaging into extracellular vesicles is common for signaling modulators that are earmarked for intercellular communication, which accounts for detection in GO:0070062 extracellular exosome. Together, these compartments position the protein where it can intercept cytosolic PKA signaling and influence nuclear responses.

4. 04

   Mechanistically, a binding-optimized inhibitor can act by sequestering or sterically occluding cAMP-dependent kinase assemblies.

   By engaging the kinase complex and its anchoring machinery, it reduces catalytic throughput and reshapes pathway topology. I hypothesize that it associates with cytosolic and membrane-tethered PKA holoenzymes and their AKAP scaffolds, forming transient inhibitory complexes that tune phosphorylation cascades. Likely partners include catalytic and regulatory PKA subunits and anchoring proteins that localize PKA to cytosolic and nuclear sites; occasional inclusion into exosomes would accompany these assemblies. This architecture causes a systems-level dampening of cAMP-driven signaling that is executed primarily in the cytosol with regulated access to the nucleus.